Publicaciones en colaboración con investigadores/as de University of Münster (76)

2024

  1. Evolution of spontaneous portosystemic shunts over time and following aetiological intervention in patients with cirrhosis

    JHEP Reports, Vol. 6, Núm. 2

2023

  1. A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets

    Neurodegenerative Disease Management, Vol. 13, Núm. 1, pp. 15-21

  2. Brain ageing in schizophrenia: evidence from 26 international cohorts via the ENIGMA Schizophrenia consortium

    Molecular Psychiatry, Vol. 28, Núm. 3, pp. 1201-1209

  3. Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary

    Neurodegenerative Disease Management, Vol. 13, Núm. 1, pp. 5-13

  4. Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence

    Multiple Sclerosis and Related Disorders, Vol. 69

  5. Large-scale analysis of structural brain asymmetries in schizophrenia via the ENIGMA consortium

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 120, Núm. 14

  6. Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET)

    Gut, Vol. 72, Núm. 8, pp. 1581-1591

2022

  1. Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data

    Multiple Sclerosis Journal, Vol. 28, Núm. 5, pp. 842-846

  2. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores

    Journal of the National Cancer Institute, Vol. 114, Núm. 1, pp. 109-122

  3. Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial

    European Journal of Neurology, Vol. 29, Núm. 3, pp. 790-801

  4. Genetic variants associated with longitudinal changes in brain structure across the lifespan

    Nature neuroscience, Vol. 25, Núm. 4, pp. 421-432

  5. Mapping genomic loci implicates genes and synaptic biology in schizophrenia

    Nature, Vol. 604, Núm. 7906, pp. 502-508

  6. Platelet number and function alterations in preclinical models of sterile inflammation and sepsis patients: implications in the pathophysiology and treatment of inflammation

    Transfusion and Apheresis Science, Vol. 61, Núm. 2

  7. The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021

    Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 28, Núm. 9, pp. 1424-1456

  8. Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis

    Multiple Sclerosis Journal

  9. Virtual Ontogeny of Cortical Growth Preceding Mental Illness

    Biological Psychiatry, Vol. 92, Núm. 4, pp. 299-313

2021

  1. Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice

    Therapeutic Advances in Neurological Disorders, Vol. 14

  2. Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight

    eLife, Vol. 10

  3. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

    The Lancet Neurology, Vol. 20, Núm. 1, pp. 49-59

  4. Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders

    JAMA Psychiatry, Vol. 78, Núm. 1, pp. 47-63